Latest Headlines

31. Guardant360 CDx Receives FDA Approval As First And Only Liquid Biopsy Companion Diagnostic For Amgen’s LUMAKRAS (sotorasib) KRAS^G12C Inhibitor For Use In Advanced Non-Small Cell Lung Cancer 5/28/2021

    Guardant Health, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved the Guardant360 CDx test as the first and only liquid biopsy companion diagnostic for tumor mutation profiling, or comprehensive genomic profiling, to identify patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who harbor the KRAS ^G12C mutation and may benefit from LUMAKRAS (sotorasib), an FDA-approved KRASG12C inhibitor developed and manufactured by Amgen. The Guardant360 CDx

32. BD Leverages Artificial Intelligence To Transform Microbiology Urine Testing 5/27/2021

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra™ lab automation incubation and imaging system that can transform the way microbiology labs approach urine culture analysis.

33. Novacyt S.A. (‘Novacyt’, The ‘Company’ Or The ‘Group’): Launch Of VersaLab Portable 5/26/2021

    Novacyt, an international specialist in clinical diagnostics, announces the expansion of its VersaLab portfolio with the launch of VersaLab Portable to provide an additional level of support in near-patient testing environments.

34. Specific Diagnostics Announces US Clinical Trials For Its Reveal Rapid Antibiotic Susceptibility Testing (AST) System 5/26/2021

    Specific Diagnostics announces today that its US clinical studies for Reveal Rapid AST System will commence at the beginning of August, and entail 3 months of data collection, followed by submission for FDA consideration of 510(k) clearance of the Reveal test.

35. QIAGEN Partners With Mirati Therapeutics Inc. To Develop KRAS^G12C Companion Diagnostic For Non-Small Cell Lung Cancer (NSCLC) 5/25/2021

    QIAGEN N.V. today announced a global collaboration with Mirati Therapeutics Inc. to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation who may benefit from treatment with adagrasib, Mirati’s investigational, highly selective and potent oral small molecule inhibitor of KRASG12C.

36. Eurofins Expands Its Global Sequencing And Mutation-Specific PCR Capabilities To Detect COVID-19 Variants Of Concern And Of Interest 5/25/2021

    As the number of types of COVID-19 Variants of Concern and of Interest increases, fast high throughput NGS sequencing is key to identify new variants while mutation specific PCR testing enables immediate detection and contact tracing. Eurofins continues to develop innovative COVID-19 testing solutions and has now reached two important milestones.

37. OptraSCAN Announces CytoSiA - A Complete Digital Solution For Scanning And Analysis Of Cytology Slides At Affordable Pricing 5/25/2021

    OptraSCAN®, the leading On-Demand Digital Pathology solution provider, today announced its intelligent solution CytoSiA for rapid yet affordable scanning and analyzing of liquid-based cytology slides and pap-smears.

38. SP Delivers World's Largest Installation Of Commercial Freeze Dryers For Diagnostics Production 5/25/2021

    SP Scientific Products (SP) has announced one of the world's largest simultaneous installation of commercial lyophilizers for use in the production of diagnostic tests. The order for SP lyophilizers was made last year by a leading global healthcare company in response to the need for an increase in SARS-CoV-2 testing.

39. Myriad Genetics Signs Definitive Agreement To Sell Myriad RBM To Q2 Solutions 5/24/2021

    Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA.

40. Vascular Institute Of The Rockies Opens First-Ever Cardiovascular Multidisciplinary Center In Colorado 5/21/2021

    Vascular Institute of the Rockies (VIR), in partnership with Advanced Heart & Vein Center (AHVC), Denver Interventional, Vascular Labs of the Rockies, and Surgical Care Affiliates, is pleased to open the first-of-its-kind building that is.